Irinotecan

Irinotecan Hydrochloride Injection USP is indicated as :  a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum.  a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy.

Irinotecan Hydrochloride Injection USP should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

1 Pediatrics Pediatrics: The safety and effectiveness of Irinotecan Hydrochloride Injection USP in the pediatric population have not been established (see 7 WARNINGS AND PRECAUTIONS). 2 Geriatrics Geriatrics: Evidence from clinical and pharmacokinetic studies suggests that patients 65 years of age or older should be closely monitored because of a greater risk of late diarrhea in this population.

ONIVYDE pegylated liposomal is indicated in: - in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, -in combination with 5-FU and LV for the treatment of metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine based therapy.